Acoramidis Shows Promise in Reversing Cardiac Disease Progression in ATTR-CM Trial
New clinical data demonstrates that Acoramidis significantly increases days alive and free from hospitalization while reversing structural disease progression in patients with transthyretin amyloid cardiomyopathy.
